Quality of Life Study in Participants With IPF Under Pirfenidone Treatment

  • Respiratory Disorder
  • Idiopathic Pulmonary Fibrosis (IPF)
Please note that the recruitment status of the study at your site may differ from the overall study status because some study sites may recruit earlier than others.
Study Status:

Completed

This study runs in
Country
  • Greece
Study Identifier:

NCT03115619 ML39259

  • General Hospital of Thessaloniki Papanikolaou; Uni Pneumonology Dept.

    570 10Greece
  • General University Hospital of Larisa; Pneumonology Clinic

    413 34Greece
  • Papanikolaou Hospital; Pneumonology Clinic

    570 10Greece
  • Sotiria Hospital for Diseases of the Chest, Academic Department of Pneumonology

    152 Mesogion115 27AthensGreece
  • University General Hospital of Athens "Attikon", B' University Pulmonary Clinic

    1 Rimini124 62ChaidariGreece
  • University General Hospital of Heraklio, Pulmonary Clinic

    IraklioGreece
  • University General Hospital of Ioannina

    455 00NeochoropouloGreece
    Show study locations

    The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

    The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

    Results Disclaimer

    Study Summary

    This multicenter, post-marketing, observational study will evaluate quality of life in participants with Idiopathic Pulmonary Fibrosis (IPF) under treatment with pirfenidone (Esbriet).

    Hoffmann-La Roche Sponsor
    N/A Phase
    NCT03115619, ML39259 Study Identifier
    Pirfenidone Treatments
    Idiopathic Pulmonary Fibrosis Condition
    Official Title

    A Multicenter, Post-Marketing, Non-Interventional, Observational Study to Evaluate Quality of Life in Patients in Greece With Idiopathic Pulmonary Fibrosis Under Treatment With Pirfenidone - The Pneumon Study

    Eligibility Criteria

    All Gender
    ≥ 18 Years Age
    No Healthy Volunteers
    Inclusion Criteria
    • Adult participants for whom pirfenidone has already been prescribed for IPF no more than 4 weeks prior to enrollment, according to their physicians' clinical decision and the terms in the SmPC
    Exclusion Criteria
    • Participants who are participating in an interventional study or have received any investigational agent in the past 4 weeks

    Clinical Research Explained

    Information about what clinical studies and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

    Find out now